Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.
Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 receptor agonists.
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of cancer and dementia,
Popular GLP-1 Drugs Are Shaping Health Beyond Weight Loss & Diabetes
In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver failure, lung failure, cardiac arrest, aspiration pneumonia and shock.
GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks
A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health benefits,
Not Just For Weight Loss: GLP-1 Drugs May Affect Addiction And Dementia Risk
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
GLP-1 weight loss drugs linked to a wide range of health benefits and risks: study
A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, including several newly found conditions linked to the GLP-1 class of weight loss and diabetes drugs.
Study finds GLP-1s had multiple health benefits
A study of more than 2 million Veterans Health Administration patient records found GLP-1 drugs lowered the likelihood of dozens of health conditions including Alzheimer's disease but also had some unexpected risks.
GLP-1s linked to wide range of health benefits: Study
A new study from the Department of Veteran Affairs, published in Nature Medicine, found that GLP-1 weight loss drugs including Mounjaro, Ozempic, Wegovy and Zepbound, may offer benefits beyond weight loss — the latest in a growing body of research legitimizing the versatility of the drug class.
New Scientist on MSN16h
GLP-1 drugs like Ozempic and Wegovy lower the risk of 42 conditions
The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...
defector21h
GLP-1 Agonists: The Defector Review
Time for your weekly edition of the Defector Funbag. Got something on your mind? Email the Funbag. And buy Drew’s book, The ...
BioPharma Dive4d
Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...
Fierce Healthcare5d
Biden names GLP-1 drugs Ozempic, Wegovy for price negotiation program
The Biden administration unveiled its list of 15 drugs, which include GLP-1 drugs Ozempic, Wegovy and Rybelsus, for the ...
GLP-1 Drugs Linked to Lower Alzheimer's Risk Amid Safety Warnings
Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight ...
24/7 Wall St. on MSN6d
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...